March 12, 2020 / 6:41 AM / a month ago

BRIEF-GenSight Biologics FY Net Loss Narrows To EUR 30.7 Mln

March 12 (Reuters) -

* ‍​FY OPERATING INCOME EUR 4.9 MILLION VERSUS EUR 4.3 MILLION YEAR AGO

* ‍​FY OPERATING LOSS EUR 30.3 MILLION VERSUS LOSS EUR 33.0 MILLION YEAR AGO

* ARE CURRENTLY FINANCED UNTIL THE END OF THIS YEAR, ALTHOUGH REVENUES FROM ADDITIONAL ATUS COULD EXTEND OUR RUNWAY INTO 2021 - CFO

* NET LOSS EUR 30.7 MILLION VERSUS EUR LOSS EUR 33.5 MILLION YEAR AGO

* ‍​2020 IS EXPECTED TO BE A PIVOTAL YEAR FOR GENSIGHT AS WE WORK WITH AUTHORITIES AND THE MEDICAL COMMUNITYTO BRING LUMEVOQ™ TO MARKET - CEO

* ‍​EXPECTS TO SUBMIT APPLICATION FOR MARKETING APPROVAL FOR LUMEVOQ (GS010) IN EUROPE IN Q3 2020

* ‍​END-FY CASH AND CASH EQUIVALENTS EUR 19.2 MILLION VERSUS EUR 26.2 MILLION YEAR AGO Source text for Eikon: [ID: nBw7YB4rfa] Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below